Fig. 2
From: The potential of deferasirox as a novel therapeutic modality in gastric cancer
Effect of deferasirox on cell cycle progression in AGS cells. a AGS cells were incubated with 0, 10, and 100 μM of deferasirox at 37 °C for 24 h. Cell cycle progression was analyzed by FACS. Deferasirox treatment for 24 h led to a dose-dependent accumulation of AGS cells in G1 phase (41.8 % at 0 μM, 53.7 % at 10 μM, and 77.2 % at 100 μM). b Western blot analysis of cell cycle-related molecules showed that deferasirox upregulated p21, p27, and p53 and downregulated cyclin D1, cyclin B, and CDK4